Could It Be MASH? Early Detection and Intervention to Improve Metabolic Outcomes
CE Information
1.5 contact hoursCompletion Time
1 hour, 30 minutesAvailable Until
July 6, 2026Posted By
NP Events
Navigate
Overview
Specialties
Acute Care, Adult, Family, and GerontologicalSubspecialties
Endocrinology, Hematology, Hospital Medicine, Nephrology, Other, and Primary CareClinical Topics
Metabolic DisordersTarget Audience
This activity is intended for endocrinologists, primary care physicians, nurse practitioners, physician associates, pharmacists, and other healthcare professionals who care for patients with risk for MASLD/MASH.
Program Learning Goal
The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with MASLD/MASH.
Learning Objectives
Upon completion of this activity, participants should be able to:
-
Implement strategies to improve screening rates of patients at risk for MASLD and MASH
-
Employ guideline-recommended noninvasive tests to diagnose, stage, and monitor patients with MASLD and MASH
-
Analyze the latest data for current and emerging pharmacotherapy options, including the role of incretin therapies, in the management of MASH and related cardiometabolic conditions
-
Apply the latest evidence, guidelines, and care pathways to develop treatment plans for patients with MASH and metabolic complications
Speakers
President, The Obesity Society
Professor of Medicine
James A. Keating Endowed Chair in Diabetes
Director, Division of Endocrinology, Diabetes & Metabolic Diseases
Department of Medicine
Medical University of South Carolina
Charleston, South Carolina
Chief, Division of Endocrinology, Diabetes and Metabolism
The University of Florida
Gainesville, Florida
Associate Professor of Clinical Medicine
Director of Liver Quality
Director of Inpatient Liver Services
Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York
CE Information
This activity offers 1.5 contact hours to attendees.
Accredited by ANCC.
Disclosures
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Program Director
Kenneth Cusi, MD, FACP, FACE
Professor of Medicine
Division of Endocrinology, Diabetes and Metabolism
University of Florida
Gainesville, Florida
Kenneth Cusi, MD, FACP, FACE: researcher: Boehringer Ingelheim, Echosens, Inventiva, LabCorp, Perspectum; consultant/advisor/speaker: 89Bio, Arrowhead, Boehringer Ingelheim, Bristol Myers Squibb, Dexcom, Echosens, GlaxoSmithKline, Lilly, MGM, Novo Nordisk, Sagimet Biosciences, Terns, Zealand.
Primary Author
Marc-André Cornier, MD, FTOS, FAHA: consultant/advisor/speaker: AstraZeneca, Biophytis, Keros, Lilly, Wave, Zyversa; researcher: Amgen, Cleery, Ionis, Keneka, Novartis; data and safety monitoring board: Advarra.
Arun Jesudian, MD: consultant/advisor/speaker: Madrigal, Mallinckrodt, Salix.
The planners and content peer reviewers from Clinical Care Options, LLCdo not have any relevant financial relationships to disclose, except AmyButts, PA-C, DFAAPA, BC-ADM, CDCES, as noted below.
Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES: consultant/advisor/speaker: Abbott, Novo Nordisk, Xeris.
Register For This Activity
OnDemand Activity Registration
Select this option to access the activity at no cost